Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

MLA

Niizeki, Takashi, et al. “Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.” Targeted Oncology, vol. 17, no. 6, Nov. 2022, pp. 643–53. EBSCOhost, https://doi.org/10.1007/s11523-022-00921-x.

APA

Niizeki, T., Tokunaga, T., Takami, Y., Wada, Y., Harada, M., Shibata, M., Nakao, K., Sasaki, R., Hirai, F., Shakado, S., Yoshizumi, T., Itoh, S., Yatsuhashi, H., Bekki, S., Ido, A., Mawatari, S., Honda, K., Sugimoto, R., Senju, T., … Tanaka, Y. (2022). Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Targeted Oncology, 17(6), 643–653. https://doi.org/10.1007/s11523-022-00921-x

Chicago

Niizeki, Takashi, Takayuki Tokunaga, Yuko Takami, Yoshiyuki Wada, Masaru Harada, Michihiko Shibata, Kazuhiko Nakao, et al. 2022. “Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.” Targeted Oncology 17 (6): 643–53. doi:10.1007/s11523-022-00921-x.